Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction

OTHER THEMES PUBLISHED IN THIS IMMUNOLOGY IN THE CLINIC REVIEW SERIES

[1]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[2]  J. Clohessy,et al.  Pro-senescence therapy for cancer treatment , 2011, Nature Reviews Cancer.

[3]  L. Ellis,et al.  Targeted therapies: Peaking beneath the surface of recent bevacizumab trials , 2011, Nature Reviews Clinical Oncology.

[4]  D. Neuberg,et al.  A dual role for the immune response in a mouse model of inflammation-associated lung cancer. , 2011, The Journal of clinical investigation.

[5]  D. Hanahan,et al.  Endogenous Myc maintains the tumor microenvironment. , 2011, Genes & development.

[6]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[7]  R. Perez-soler,et al.  Treatment of non-small-cell lung cancer with erlotinib or gefitinib. , 2011, The New England journal of medicine.

[8]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[9]  Laurence Zitvogel,et al.  Immune parameters affecting the efficacy of chemotherapeutic regimens , 2011, Nature Reviews Clinical Oncology.

[10]  L. Coussens,et al.  The Tumor-Immune Microenvironment and Response to Radiation Therapy , 2010, Journal of Mammary Gland Biology and Neoplasia.

[11]  N. Restifo.  Can antitumor immunity help to explain "oncogene addiction"? , 2010, Cancer cell.

[12]  Kavya Rakhra,et al.  CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. , 2010, Cancer cell.

[13]  J. Qiu,et al.  Mature B Cells Are Critical to T-cell-mediated Tumor Immunity Induced by an Agonist Anti-GITR Monoclonal Antibody , 2010, Journal of immunotherapy.

[14]  K. Flaherty,et al.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.

[15]  D. Felsher,et al.  The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. , 2010, Genes & development.

[16]  H. Stein,et al.  Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. , 2010, Cancer cell.

[17]  Luigi Naldini,et al.  FcRgamma activation regulates inflammation-associated squamous carcinogenesis. , 2010, Cancer cell.

[18]  L. Coussens,et al.  Lymphocytes in cancer development: polarization towards pro-tumor immunity. , 2010, Cytokine & growth factor reviews.

[19]  S. Rosenberg,et al.  Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells , 2010, Journal of immunotherapy.

[20]  L. Coussens,et al.  CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. , 2009, Cancer cell.

[21]  J. Blay,et al.  Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. , 2009, Cancer research.

[22]  J. Xu,et al.  Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. , 2009, Journal of Hepatology.

[23]  P. Muranski,et al.  Adoptive immunotherapy of cancer using CD4(+) T cells. , 2009, Current opinion in immunology.

[24]  T. Hambley,et al.  Targeted cancer therapeutics. , 2009, Cancer research.

[25]  D. Wink,et al.  Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. , 2008, Cancer research.

[26]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[27]  Jonathan Melamed,et al.  Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence , 2008, Cell.

[28]  D. Peeper,et al.  Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network , 2008, Cell.

[29]  M. Schwaiger,et al.  TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. , 2008, Cancer cell.

[30]  Dean W. Felsher,et al.  Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas , 2008, PloS one.

[31]  Sreenath V. Sharma,et al.  Oncogene addiction: setting the stage for molecularly targeted cancer therapy. , 2007, Genes & development.

[32]  J. Aguirre-Ghiso,et al.  Models, mechanisms and clinical evidence for cancer dormancy , 2007, Nature Reviews Cancer.

[33]  G. Evan,et al.  Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors , 2007, Nature Medicine.

[34]  Aleksandra M. Michalowska,et al.  Transforming Growth Factor-β Can Suppress Tumorigenesis through Effects on the Putative Cancer Stem or Early Progenitor Cell and Committed Progeny in a Breast Cancer Xenograft Model , 2007 .

[35]  Dean W. Felsher,et al.  Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation , 2007, Proceedings of the National Academy of Sciences.

[36]  K. Lim,et al.  Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. , 2007, Genes & development.

[37]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[38]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[39]  M. Sporn,et al.  The tumour microenvironment as a target for chemoprevention , 2007, Nature Reviews Cancer.

[40]  Sreenath V. Sharma,et al.  “Oncogenic Shock”: Turning an Activated Kinase against the Tumor Cell , 2006, Cell cycle.

[41]  Shu Shun Li,et al.  Endogenous thrombospondin-1 is a cell-surface ligand for regulation of integrin-dependent T-lymphocyte adhesion. , 2006, Blood.

[42]  E. Passegué,et al.  Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch , 2006, Proceedings of the National Academy of Sciences.

[43]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[44]  G. Evan,et al.  The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. , 2006, Genes & development.

[45]  Y. Kawakami,et al.  The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells , 2006, The Journal of experimental medicine.

[46]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[47]  David P. Davis,et al.  Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. , 2006, Cancer research.

[48]  Manuela Gariboldi,et al.  Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[49]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[50]  L. Coussens,et al.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.

[51]  Robert B Boxer,et al.  Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. , 2004, Cancer cell.

[52]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[53]  Geoffrey D. Young,et al.  The Tryptophan-rich Motifs of the Thrombospondin Type 1 Repeats Bind VLAL Motifs in the Latent Transforming Growth Factor-β Complex* , 2004, Journal of Biological Chemistry.

[54]  Christopher H. Contag,et al.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.

[55]  Stefan Wirtz,et al.  TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .

[56]  R. Kiesslich,et al.  TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. , 2004, Immunity.

[57]  D. Bar-Sagi,et al.  Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. , 2004, Cancer cell.

[58]  A. Balmain,et al.  Characterizing the Protective Component of the αβ T Cell Response to Transplantable Squamous Cell Carcinoma , 2004 .

[59]  D. Felsher.  Reversibility of oncogene-induced cancer. , 2004, Current opinion in genetics & development.

[60]  Koichi Yamazaki,et al.  CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non‐small cell lung cancers , 2003, Cancer science.

[61]  Dean W. Felsher,et al.  Cancer revoked: oncogenes as therapeutic targets , 2003, Nature Reviews Cancer.

[62]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[63]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[64]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[65]  J. Holgersson,et al.  T lymphocyte expression of thrombospondin‐1 and adhesion to extracellular matrix components , 2002, European journal of immunology.

[66]  R. Vile.  Faculty Opinions recommendation of IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. , 2001 .

[67]  Mina J. Bissell,et al.  Putting tumours in context , 2001, Nature Reviews Cancer.

[68]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[69]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[70]  Andrew V. Nguyen,et al.  Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.

[71]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[72]  G. Beatty,et al.  IFN-γ-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN-γ1 , 2001, The Journal of Immunology.

[73]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[74]  D. Felsher,et al.  Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.

[75]  L. Chin,et al.  Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.

[76]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[77]  D. Levy,et al.  Proto-oncogene PML controls genes devoted to MHC class I antigen presentation , 1998, Nature.

[78]  D. Scadden.  AIDS-related malignancies. , 1998, Current opinion in oncology.

[79]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[80]  H. Adami,et al.  Ulcerative colitis and colorectal cancer. A population-based study. , 1990, The New England journal of medicine.

[81]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[82]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.

[83]  Aleksandra M. Michalowska,et al.  Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. , 2007, Cancer research.

[84]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[85]  A. Balmain,et al.  Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma. , 2004, The Journal of investigative dermatology.

[86]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.

[87]  W. Frankel,et al.  Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. , 2003, Cancer immunity.

[88]  Lewis L Lanier,et al.  Natural killer cells and cancer. , 2003, Advances in cancer research.

[89]  G. Beatty,et al.  IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. , 2001, Journal of immunology.

[90]  D. Tenen,et al.  Reversibility of acute B-cell leukaemia induced by BCR–ABL1 , 2000, Nature Genetics.

[91]  A. Ekbom.  Ulcerative Colitis and Colorectal Cancer , 1991 .

[92]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.